Advertisement

Reactions Weekly

, Volume 1765, Issue 1, pp 47–48 | Cite as

Antivirals/immunosuppressants

Cytomegalovirus infection leading to graft loss and development of drug resistance: case report
Case report
  • 40 Downloads

A 43-year-old woman developed cytomegalovirus (CMV) infection leading to graft loss while receiving immunosuppressive treatment with tacrolimus, mycophenolate mofetil, methylprednisolone and basiliximab. Additionally, she developed antiviral resistance to valganciclovir for CMV prophylaxis and ganciclovir, cidofovir and foscarnet for CMV infection [routes not stated; not all dosages stated].

The CMV seronegative woman, who had end-stage renal failure due to obstructive renal disease, underwent a kidney transplantation from a CMV-seropositive donor. She had been receiving immunosuppressive treatment with tacrolimus, mycophenolate mofetil [initial dosage not stated], methylprednisolone and induction therapy with basiliximab. On post-transplant day 5, she started receiving valganciclovir [Valcyte] 450mg once a day for CMV prophylaxis. One week post-transplantation, CMV-PCR was found to be negative in blood, and her kidney function was found to be excellent (serum creatinine 1.0 mg/dL and...

Reference

  1. Andrei G, et al. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss. Antiviral Research 168: 203-209, Aug 2019. Available from: URL: http://doi.org/10.1016/j.antiviral.2019.06.004 - Belgium

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations